ZYPHORE THERAPEUTICS
LIVE

Serial Number

99352357

Owner

Zyphore Therapeutics, Inc.

Attorney

Ava R. Shelby

Filing Date

Aug 22, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ZYPHORE THERAPEUTICS Trademark

Serial Number: 99352357

ZYPHORE THERAPEUTICS is a trademark filed by Zyphore Therapeutics, Inc. on August 22, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Zyphore Therapeutics, Inc.

200 Berkeley St, 18th Flr
Boston, MA 02116

Entity Type: 03

Trademark Details

Filing Date

August 22, 2025

Registration Date

Not Registered

Published for Opposition

March 24, 2026

Goods & Services

Enzymes for medical purposes; engineered enzymes for medical purposes; enzyme substrates for medical purposes; therapeutic pharmaceuticals for the treatment and prevention of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations for the treatment and prevention of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; drug delivery agents that facilitate delivery and efficacy of pharmaceuticals, namely, drug delivery agents consisting of enzymes that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical and biological preparations for delivering therapeutic agents, namely, enzymes for the treatment of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; drug carriers for medical use, namely, drug delivery agents consisting of enzymes that facilitate the delivery of pharmaceutical preparations for delivering drugs to human cells, tissues and organs.

Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; drug discovery services; development of pharmaceutical and therapeutic preparations and medicines; research and development in the pharmaceutical and biotechnology fields, namely, research and development for the treatment of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; research and development in the field of biotechnology; medical and scientific research in the field of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes.

Enzyme preparations for use in the medical industry; enzyme stabilizers; enzyme substrates for scientific purposes.

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 19, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 24, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 24, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 18, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 3, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 3, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 3, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 3, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 3, 2026 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 14, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 14, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 14, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 7, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 24, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 22, 2025 MAFR
NEW APPLICATION ENTERED
Aug 22, 2025 NWAP